
Abbott Laboratories, Johnson & Johnson, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. “Medical stocks” refers to shares of publicly traded companies that develop, manufacture, or provide healthcare-related products and services — including pharmaceutical and biotechnology firms, medical device makers, diagnostic companies, hospitals, and healthcare service providers. Investors watch these stocks for growth potential tied to drug approvals, patents, and innovation, but also consider regulatory, clinical trial, reimbursement, and policy risks that can cause significant price volatility. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Abbott Laboratories (ABT)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Read Our Latest Research Report on JNJ
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read Our Latest Research Report on LLY
Read More
- MarketBeat’s Top Five Stocks to Own in January 2026
- Cash Is King: DigitalBridge Is the Ultimate Defensive Play
- Why Taiwan Semiconductor and Meta Could Be the Hidden Bull Case for Broadcom
- Forget the Chips, Buy Memory: Why AI Money Is Moving to Storage
- Poll Reveals: Most Popular Fast-Food Restaurants for Valentine’s Day on a Budget (2026)
- A Hidden Monopoly: Why AI Can’t Exist Without Cadence
